IMMP1L

Across TCGA pan-cancer cohorts, IMMP1L Mutation is linked to patient survival in 3 of 34 cancer types, making it a survival-associated IMMP1L data layer compared with 24 for mass-spec protein and 3 for mass-spec protein.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher IMMP1L Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated IMMP1L expression acts as an unfavorable survival marker.

HNSC, COAD, and PRAD are the cancer types where IMMP1L Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	OS	Median	II,III,IV	0.079	0.756	<.001	30	view →
COAD	DFS	Median	All	0.223	0.690	.010	12	view →
PRAD	DFS	Median	All	0.085	0.774	<.001	6	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

IMMP1L–HNSC (OS)

Open the HNSC breakdown →